LENZ Therapeutics, Inc.

LENZ Therapeutics, Inc.

LENZ·NASDAQ

$7.13

-0.14%
HealthcareBiotechnology

LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.

At a Glance

Live Snapshot
Market Cap$223.56M
EPS-2.8500
P/E Ratio-5.61
Earnings Date07/29/2026

lenz

Net Common Stock Issuance

Last Annual Value

149.75M

3-Year CAGR

531%

5-Year CAGR

38%

10-Year CAGR

%

LENZ Therapeutics, Inc.

LENZ Therapeutics, Inc. Competitors Analysis of Net Common Stock Issuance

LENZ · NASDAQ
CompanyNet Common Stock Issuance
CAGR 3Y
CAGR 5Y
CAGR 10Y
149.75M
N/A-18.5%N/A 
SVRA logo
Savara Inc.
NASDAQ:SVRA
135.44M
18.0%2.1%N/A
RZLT logo
Rezolute, Inc.
NASDAQ:RZLT
107.33M
105.7%21.2%34.9%
5.68M
-6.3%N/AN/A
5.72M
-42.3%-46.8%N/A
2.27M
-78.0%-35.5%N/A
0.00
N/AN/AN/A
139.51M
497.2%N/AN/A
8.10M
74.0%-46.3%N/A
LENZ Therapeutics, Inc.

LENZ Therapeutics, Inc. Fair Value Envelope

LENZ · NASDAQ

Our analysis suggests that LENZ has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $7.13, this represents a potential HIDDEN relative to our calculated worth for LENZ Therapeutics, Inc..

Intrinsic Value
Current Price: $7.13